ClinicalTrials.gg
Active, not recruitingNCT06646601ArTERREUpdated Nov 10, 2026

A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering From Cardio-neurovascular Pathology and to Those Involved in the Action.

An interventional study of Intervention of prevention in Vascular Disease, Cardiovascular and Atrial Fibrillation (AF), sponsored by Assistance Publique Hopitaux De Marseille. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2024, registered Oct 2024).
Updated Nov 10, 2026Now Active, not recruitingStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
157
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Vascular Diseases with a site in France — 11 open to participants now, 19 under way, 4 of them phase 3. Vascular Diseases · France.

Planned enrollment
25th of 43
157 · median 281
Started
2024
with 1 other
No phase
28 of 70
3 open now
Primary completion
2026-03
later than 4 of 18 live
Registered
65th of 70
by date
Lead sponsor
2 of 70
Assistance Publique Hopitaux De Marseille

Among the 70 studies in Vascular Diseases with a site in France, this one is the 25th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 with no phase, reaches primary completion later than 4 of the 18 other live ones, and was the 65th registered.

Vascular Diseases

694 studies on the registry are indexed under Vascular Diseases; 127 are open to participants now.

Browse Vascular Diseases studies →

Open to participants now

11 of the 70 studies in Vascular Diseases with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Vascular Diseases with a site in France, or all of them as a file.
02

Study summary

A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.

03

Conditions studied

  • Vascular Disease
  • Cardiovascular
  • Atrial Fibrillation (AF)
  • Heart Failure NYHA Class II
  • Cardiomyopathies
  • Stroke, Ischemic
  • Hypertension Resistant to Conventional Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years old;
  • living in the vicinity (+-20 km) of Gap, Laragne-Montéglin, Veynes and Clermont-Ferrand;
  • having been invited to take part in the intervention by the caregivers of the medical structures
  • suffering from an ALD based on CNAM medical criteria (stroke, AOMI, rhythm disorders, valvular heart disease, congenital heart disease, stage I and II heart failure), severe hypertension, chronic coronary disease)

Exclusion criteria

Exclusion Criteria:

  • heart failure based on CNAM medical criteria (ALD n°5) stage III and IV according to classification ;
  • with a to physical activity ;
  • living in an institution;
  • unable to walk more than 100 m independently;
  • Alzheimer's disease or other dementias based on CNAM medical criteria ;
  • with an unlabelled cognitive impairment limiting comprehension.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
157 participants (estimated)

Study arms

  • Experimental
    Multidisciplinary preventive action and questionnaries

    A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops and questionnaries

    Other: Intervention of prevention

  • No intervention
    No intervention but questionnaries

    Refuse the intervention and answers questionnaries about why

Interventions

  • OtherIntervention of prevention

    A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.

06

What researchers measure

Primary outcomes

  1. Acceptance rate of intervention

    Assessing the acceptability of a multidisciplinary intervention combining gardening activities, APA and nutrition workshops, organized around a therapeutic garden, by patients suffering from cardio-neurovascular pathologies and the interveners of the action.

    Time frame: From enrollment to the end of treatment at 6 months

  2. Identification of the obstacles and facilitators for intervention

    Identify the obstacles and factors facilitating patients' initial adhesion to and commitment to the scheme, and those influencing the implementation of the action by those involved, i.e. the facilitators and caregivers involved.

    Time frame: From enrollment to the end of treatment at 6 months

Secondary outcomes

  1. Assessing the impact of the intervention

    Assess the impact of the intervention on quality of life, adoption of new lifestyle habits (PA and Mediterranean diet), depressive symptoms and physical performance, taking into account any adverse effects.

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 site
  • Gap +/- 20 km
    Gap, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Mar 2026, 23 months.

Of 104 non-industry interventional studies with no phase under Vascular Diseases, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 148 studies reached it within 33 months; a quarter within 19 and three quarters within 57.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 17, 2024
StartActual
Apr 9, 2024
Primary completionActual
Mar 31, 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Study completion
Oct 2026→Oct 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    Study completion Oct 2026→Oct 2027
    + 5 other changes: identifiers, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06646601
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Apr 9, 2024
Primary completion
Mar 31, 2026
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion